Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 10/20 | 0.76 |
| ▸ | MMP2 | P08253 | 10/20 | 0.76 |
| ▸ | MMP9 | P14780 | 10/20 | 0.76 |
| ▸ | EGFR | P00533 | 8/20 | 0.76 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.56 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819695 | 1.00 | MMP1 (0.76) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL30159590 | 1.00 | MMP1 (0.76) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL3180639 | 1.00 | MMP1 (0.76) | MMP1MMP2MMP9EGFRMAOB | |
| N-(2-Fluorophenyl)Cinnamamide SCHEMBL1967607 | 0.86 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| N-(2-Fluorophenyl)Cinnamamide SCHEMBL1967609 | 0.86 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL705905 | 0.85 | MMP1 (0.80) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL705904 | 0.85 | MMP1 (0.80) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL2821162 | 0.83 | MMP1 (0.76) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL2821167 | 0.83 | MMP1 (0.76) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL10492424 | 0.81 | MMP1 (0.80) | MMP1MMP2MMP9EGFRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111205281-B | Heterocyclic compounds and their use | 阮富强 | 2022-12-27 | — | — | CN | disclosed |
| CN-111205281-A | Heterocyclic compounds and their use | 阮富强 | 2020-05-29 | — | — | CN | disclosed |
| US-10442799-B1 | Heterocyclic compounds and uses thereof | RUAN FUQIANG (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190308963-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | RUAN FUQIANG (US) | 2019-10-10 | — | — | US | disclosed |
| WO-2017025371-A1 | PROCESS FOR THE PREPARATION OF 5-AMINO-QUINOLIN-2(1H)-ONES AND THEIR TAUTOMER FORMS 5-AMINO-QUINOLIN-2-OLS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-16 | — | — | WO | disclosed |
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| EP-2041145-B1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | GLAXO GROUP LIMITED (GB) | 2010-10-07 | — | — | US | disclosed |
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2136807-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| EP-2137195-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| EP-2041145-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| EP-2029612-A1 | SUBSTITUTED 1-METHYL-1H-QUINOLIN-2-ONES AND 1-METHYL-1H-1,5-NAPHTHYRIDIN-2-ONES AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008128953-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008125594-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125594-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008006648-A1 | SUBSTITUTED 1-METHYL-1H-QUINOLIN-2-ONES AND 1-METHYL-1H-1,5-NAPHTHYRIDIN-2-ONES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008003690-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308963-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRD4, BICRA, BET1 | MMP1 3840/4885MMP2 3671/4885MMP9 2604/4885 |
| US-10442799-B1 | Heterocyclic compounds and uses thereof | BRD4, BICRA, BET1 | MMP1 3840/4885MMP2 3671/4885MMP9 2604/4885 |
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | NRDC, NDC1, NANS | MMP1 3635/4885MMP2 2307/4885MMP9 2981/4885 |
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | TOP1, TOP2A, NDC1 | MMP1 3354/4885MMP2 3079/4885MMP9 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.